OPRX OptimizeRx Corp

OptimizeRx to Participate at Investor Conferences in November

OptimizeRx to Participate at Investor Conferences in November

ROCHESTER, Mich., Oct. 20, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has been invited to participate in two investor conferences being held in November.

Event:

Attendance Date: November 11, 2020

Format: Virtual 1x1 and small group meetings

Registration: Email  or click .

Event:

Attendance Date: November 12, 2020

Format: Virtual 1x1 meetings

Registration: Please contact your Stifel institutional sales representative.

OptimizeRx management is scheduled to participate in virtual one-on-one meetings with institutional investors and analysts at both conferences.

Management will discuss the company’s recently preliminary results for the third quarter of 2020. The company expects record revenue of more than $10.0 million, up over 100% versus the same year-ago quarter, along with positive non-GAAP net income.

They will review how this growth is being driven organically by a combination of enterprise deals and tactical programs, as its life science customers increasingly see the value in transparent access to physicians and patients via the OptimizeRx digital health platform.

To schedule a virtual one-on-one meeting with OptimizeRx, you may submit your request via the links provided upon your registration for the conferences. For any questions about the company, please contact Ron Both of CMA at (949) 432-7557 or submit your request .

About Roth Capital Partners        

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit .

About Stifel

Stifel is a full-service investment firm with a distinguished history of providing securities brokerage, investment banking, trading, investment advisory, and related financial services to individual investors, institutions, corporations, and municipalities. Established in 1890 and headquartered in St. Louis, Missouri, Stifel is one of the nation’s leading firms.

For more information about Stifel, visit .

About OptimizeRx

OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.

For more information, follow the company on ,  or visit . 

Important Cautions Regarding Forward Looking Statements        

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

OptimizeRx Contact 

Doug Baker, CFO

Tel (248) 651-6568 (x807)

 

Media Relations Contact 

Maira Alejandra, Media Relations Manager

Tel (754) 245-7070 

Investor Relations Contact 

Ron Both, CMA 

Tel (949) 432-7557 

EN
20/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OptimizeRx Corp

 PRESS RELEASE

OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Co...

OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, March 5, 2026, at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter period ended December 31, 2025. The financial results will be issued in a press release prior to the call. Optimiz...

 PRESS RELEASE

OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity R...

OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing Life science marketers will be able to better measure the exposed audiences for a more complete, accurate, and transparent view of campaign engagement and effectiveness WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life science companies reach and engage healthcare professionals (HCPs) and patients, today announced at CES 2026 a data collaboration with Experian, a leading global data an...

 PRESS RELEASE

OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network

OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network Strategic Partnerships Add Exclusivity in Leading EHR, e-Prescription, and Technology Companies, Increasing NPI Reach by 37% WALTHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced four new partner agreements that meaningfully expand the Company’s in-workflow point-of-care (POC) network, fortify its long-term comp...

 PRESS RELEASE

OptimizeRx Reports Third Quarter 2025 Financial Results and Increases ...

OptimizeRx Reports Third Quarter 2025 Financial Results and Increases Fiscal Year 2025 Guidance -   Q3 revenue of $26.1 million, increased 22% year-over-year-   Q3 gross profit increased 30% year-over-year to $17.5 million-   Increases full year 2025 guidance to a revenue range between $105 million and $109 million and adjusted EBITDA range between $16 million and $19 million-   Introduces 2026 guidance with a revenue range between $118 million and $124 million and adjusted EBITDA range between $19 million and $22 million-   Paid off an incremental $2 million in principal from term loan sub...

 PRESS RELEASE

OptimizeRx Sets Third Quarter 2025 Conference Call for November 6, 202...

OptimizeRx Sets Third Quarter 2025 Conference Call for November 6, 2025, at 4:30 p.m. ET WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, November 6, 2025, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx manageme...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch